Wealth Enhancement Advisory Services
RCKT icon

Wealth Enhancement Advisory Services’s Rocket Pharmaceuticals RCKT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Buy
91,568
+10,700
+13% +$35.6K ﹤0.01% 3027
2026
Q1 		$287K Buy
80,868
+62,638
+344% +$249K ﹤0.01% 2821
2025
Q4 		$64.5K Buy
18,230
+1,102
+6% +$3.77K ﹤0.01% 3504
2025
Q3 		$53.8K Buy
+17,128
New +$53.9K ﹤0.01% 3418

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wealth Enhancement Advisory Services's RCKT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Rocket Pharmaceuticals (RCKT) stake by 13% in Q2 2026, buying an estimated $35.6K and bringing the position to 91,568 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #3027.

Wealth Enhancement Advisory Services first reported a position in RCKT in Q3 2025 and has held it in 4 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Wealth Enhancement Advisory Services held 91,568 shares of Rocket Pharmaceuticals worth $358K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 10,700 Rocket Pharmaceuticals shares in Q2 2026, an estimated $35.6K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3027 holding.
  • Wealth Enhancement Advisory Services first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.